LF

LifeVantage CorpNASDAQ LFVN Stock Report

Last reporting period 30 Jun, 2024

Updated 01 Nov, 2024

Last price

Market cap $B

0.136

Micro

Exchange

XNAS - Nasdaq

LFVN Stock Analysis

LF

Avoid

Based on Eyestock quantitative analysis, LFVN`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

74/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-69.8 %

Greatly overvalued

Market cap $B

0.136

Dividend yield

1.54 %

Shares outstanding

12.717 B

LifeVantage Corp. engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and personal care products. The company is headquartered in Lehi, Utah and currently employs 259 full-time employees. The company went IPO on 2012-09-12. The firm's dietary supplements include its flagship Protandim family of products, LifeVantage Omega+, ProBio, IC Bright, and Daily Wellness dietary supplements. The Protandim product line includes Protandim NRF1 Synergizer, Protandim Nrf2 Synergizer, and Protandim NAD Synergizer. TrueScience is its line of skin, bath and body, target relief, and hair care products; Petandim, its companion pet supplement formulated to combat oxidative stress in dogs; Axio, its nootropic energy drink mixes, and PhysIQ, its smart weight management system, which includes PhysIQ Fat Burn, PhysIQ Prebiotic and PhysIQ Whey Protein, all formulated to aid in weight management.

View Section: Eyestock Rating